ReadSpeaker VoiceLab Powers Sonos Voice Control Custom Voice
17.5.2022 15:00:00 EEST | Business Wire | Press release
ReadSpeaker, the most trusted, independent digital voice partner for global businesses, today announced that Sonos, the world’s leading sound experience company, has selected the ReadSpeaker VoiceLab to create a custom voice for Sonos Voice Control, the brand’s voice assistant. Sonos selected VoiceLab, ReadSpeaker’s custom voice production unit, because of the company’s proven experience and expertise in state-of-the-art, AI-driven text-to-speech.
Leading consumer brands are looking to develop their own voice assistants to provide consistently on-brand, personalized and engaged automated customer experiences. Those with a visionary strategy and commitment to consumer privacy, like Sonos, are understanding the broader importance of AI-driven digital voice in helping expand their business and meet consumer needs and expectations, even as they quickly evolve.
The ReadSpeaker VoiceLab managed the development process, including carrying out recordings with Giancarlo Esposito, processing the recorded data, training Deep Neural Networking (DNN) models on that data, and managing quality control, delivery, and all necessary quality assurance steps. Because of the technicality of the voice recordings required to build the custom voice, which requires speech to be delivered in an extremely consistent way that prioritizes precise articulation and style, ReadSpeaker’s VoiceLab experts worked closely with Esposito throughout every stage of the process.
A key challenge in the development of this custom voice was the need for it to comprehend and pronounce non-standard text content that is often found in the music industry. It was also critical that the assistant was able to read artists’ track or album information in numerous languages. The VoiceLab team worked closely with Sonos and Esposito to optimize the speech output for this massively broad domain.
Sonos Voice Control is an entirely new voice experience that delivers fast, accurate hands-free control of your music and your Sonos system with unmatched privacy. Designed with privacy at its core, Sonos Voice Control is the simplest way to control your music, offering complete command of your Sonos system using only your voice. Sonos Voice Control works on every voice-capable Sonos speaker, processing requests entirely on the device. No audio or transcript is sent to the cloud, stored, listened to or read by anyone. Available from June 1 in the US and later this year in France on all voice capable Sonos products, Sonos Voice Control is compatible with Sonos Radio, Apple Music, Amazon Music, Deezer, and Pandora at launch. More services and markets will follow.
“We selected ReadSpeaker to power the custom voice for Sonos Voice Control for a variety of reasons, not least of which was their ability to work closely with us from the development phase all the way through delivery,” said Joseph Dureau, Vice President, Voice Experience, at Sonos. “ReadSpeaker’s approach to custom voice is innovative and extremely thorough – which is exactly what we required for this project – and the company’s dedicated linguistic team has been a critical tool for us throughout this project.”
“As brands become increasingly aware that, much like a visual logo, a custom voice ensures consistently engaging, on-brand interactions across touchpoints, our VoiceLab is developing voices that speak to their brand persona and create unique experiences,” said Roy Lindemann, CMO and CCO EMEA, at ReadSpeaker. “With more consumers leveraging digital voice every day for everything from making purchases to choosing which playlist to listen to, having a custom branded voice is becoming table stakes for delivering a quality, personalized CX in real time. By partnering with Sonos, we are helping to bring yet another brand’s voice to life in an exciting, innovative way.”
Watch the SVC Custom Voice “behind the scenes” video here: https://www.youtube.com/watch?v=vwJ8Ub10arQ
For more information about the ReadSpeaker VoiceLab, visit www.readspeaker.ai/solutions/custom-text-to-speech-tts-voices/.
About ReadSpeaker:
ReadSpeaker is the most trusted independent digital voice partner for global brands, institutions, and organizations. With over 20 years’ experience, ReadSpeaker’s AI-powered text-to-speech solutions and expert assistance enhance the accessibility of digital content and enable more user-friendly and engaging interactions with technology. The company’s flexible cloud and on-premise solutions bring over 110 expressive, humanlike synthetic voices in more than 35 languages to any application or device. The company consistently maintains its uncompromising commitment to data privacy and has so far speech enabled over 10,000 voice applications worldwide.
ReadSpeaker’s digital voice design brand, readspeaker.ai, helps agencies, integrators, and developers to enhance CX and drive sales through consistently engaging, on-brand interactions across touchpoints. For more information, go to readspeaker.ai and follow the company on Twitter and LinkedIn.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220517005419/en/
Contact information
ReadSpeaker:
Victoria Newell
V2 Communications for ReadSpeaker
readspeaker@v2comms.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Pivotal Trial Data for EP0031 (A400), a Next-Generation Selective RET Inhibitor (SRI), in RET Positive Advanced NSCLC, to be Presented at ASCO 202622.5.2026 12:18:00 EEST | Press release
Ellipses Pharma (“Ellipses”), a global oncology drug development company with a pipeline of innovative programmes, announced today that its partner, Kelun-Biotech, is presenting pivotal trial data for EP0031/A400, for the potential treatment of RET-fusion positive Non-Small Cell Lung Cancer (NSCLC), at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting Chicago, May 29 to June 2. Efficacy and safety of lunbotinib (A400/EP0031), a next-generation selective RET inhibitor (SRI), from a pivotal phase Ⅱ study in patients with advanced RET-fusion positive non-small cell lung cancer (NSCLC), will be presented as an oral presentation scheduled on May 29, 2026, 14:36-14:48 local time (Abstract #8505: Lung Cancer – Non-Small Cell Metastatic). The oral presentation of these data at the prestigious ASCO annual meeting, represents another major milestone in the global development of EP0031/A400 as a next generation SRI. The data were generated in Kelun-Biotech’s Phase 2 study (NCT0
FPT Launches Flezi Foundry™, Advancing AI-Augmented Delivery for Global Enterprises22.5.2026 11:11:00 EEST | Press release
Global IT corporation FPT announced the launch of Flezi Foundry™ (FPT Digital Foundry™), an AI-augmented delivery platform for software development and IT operations. Built around a governed Service-as-a-Software model, the platform combines autonomous AI agents, human expert oversight, secure infrastructure, and outcome-based delivery mechanisms to help enterprises modernize technology delivery as AI agents become part of software engineering and IT operations. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521235556/en/ Flezi Foundry applies Agentic Engineering, a structured delivery approach for software development and IT operations. The model brings AI agents into delivery workflows with human supervision, governance, transparency, and performance measurement built into the process. Flezi Foundry operates through two service modes: Agentic Development Lifecycle (ADLC) supports software development by using specialize
Boomi Named One of The Sunday Times Best Places to Work 202622.5.2026 09:00:00 EEST | Press release
Boomi, the data activation company for AI, has today been named one of The Sunday Times Best Places to Work 2026 in the Medium Organisation category. The prestigious annual list, produced by The Sunday Times in partnership with global workplace analytics company WorkL, recognises the UK's finest employers based entirely on direct employee feedback, making it one of the most credible and transparent employer benchmarks in the country. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521069859/en/ Boomi Named One of The Sunday Times Best Places to Work 2026 Boomi's results speak to a workplace culture that goes well beyond industry norms. The company achieved an average employee happiness score of 86%, rated Excellent, with consistent scores across all six dimensions of WorkL's framework. Most strikingly, Boomi's flight risk, the proportion of employees who may be considering leaving, stood at just 3%, against a technology se
LTM Has Issued an Offer to Acquire Randstad’s Technology and Consulting Services Business in Europe and Australia to Scale Domain-Driven Solutions and AI Services22.5.2026 08:09:00 EEST | Press release
LTM and Randstad announced that LTM has issued an offer to acquire Randstad’s Technology and Consulting Servicesbusiness in France, Germany, Belgium, Luxembourg and Australia, representing USD 500+ million (€469M) in annual revenue, to scale domain-driven solutions and AI services in the region. The proposed acquisition would expand LTM’s presence in key markets, primarily across Aerospace & Defence, Automotive, Utilities and BFS. It would enable local domain expertise and complementary regional capabilities in domain-driven digital engineering, cybersecurity and IoT, supported by onshore and nearshore delivery through centers in Romania and Portugal. This would create a more diversified portfolio for LTM – expanding its scale in Europe and Australia, enhancing its position in regulated and high-growth verticals through marquee customer relationships. The deal would augment LTM’s global AI-centric capabilities with local domain and near-shore expertise crucial for delivering digital an
Polpharma Biologics and Tuteur Sign Licensing Agreement for a Biosimilar for Autoimmune Diseases22.5.2026 08:00:00 EEST | Press release
Polpharma Biologics, a leading biopharmaceutical company specializing in the development and manufacturing of biosimilars, today announced the signing of a landmark licensing agreement with Argentina-based Tuteur. Under this strategic partnership, Tuteur will obtain exclusive rights to commercialize a biosimilar for autoimmune diseases across Latin America (LATAM), excluding Brazil. Polpharma Biologics will retain full responsibility for the development and manufacturing of the biosimilar. Tuteur will be responsible for commercialization, marketing, and distribution in the licensed territories. This collaboration reflects a shared commitment to expanding patient access to high-quality, affordable biological therapies across the region. “Partnering with Tuteur represents an important step in advancing our mission to broaden access to biosimilars globally,” said Anjan Selz, CEO of Polpharma Biologics. “With their strong regional expertise and commercial capabilities in LATAM, we are well
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
